Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
estradiol acetate
|
| gptkbp:ATCCode |
G03CA03
|
| gptkbp:contraindication |
gptkb:cancer
undiagnosed vaginal bleeding active thromboembolic disorders |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:duration |
3 months per ring
|
| gptkbp:form |
vaginal ring
0.05 mg/day 0.10 mg/day |
| https://www.w3.org/2000/01/rdf-schema#label |
Femring
|
| gptkbp:indication |
menopausal symptoms
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Warner_Chilcott
|
| gptkbp:mechanismOfAction |
estrogen receptor agonist
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:regulates |
approved
|
| gptkbp:routeOfAdministration |
vaginal
|
| gptkbp:sideEffect |
abdominal pain
headache breast tenderness vaginal discharge |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
hot flashes
vaginal atrophy |
| gptkbp:bfsParent |
gptkb:Warner_Chilcott
|
| gptkbp:bfsLayer |
7
|